The official journal of CSACI
Severe exacerbation of facial dermatitis with swelling following introduction of abrocitinib in a patient with atopic dermatitis
Abrocitinib, an oral small-molecule Janus kinase 1 (JAK1) inhibitor, has been widely accepted for the treatment of moderate-to-severe atopic dermatitis (AD). Currently there is a paucity of data on the adverse...